Early onset AD harbors a greater tau pathology burden and faster progression than late onset AD [61, 62], and studies have shown that age could affect the levels of p-tau [63] and the amount of [18F]flortaucipir uptake [18, 64]. This evidence concerns the gene MAPT and Alzheimer disease.